People: Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

93.00CHF
17 Apr 2014
Price Change (% chg)

CHF3.05 (+3.39%)
Prev Close
CHF89.95
Open
CHF91.50
Day's High
CHF93.05
Day's Low
CHF90.50
Volume
202,204
Avg. Vol
106,806
52-wk High
CHF129.80
52-wk Low
CHF47.60

Search Stocks

Summary

Name Age Since Current Position

Werner Henrich

70 2001 Chairman of the Board of Directors

Ronald Scott

58 2013 Chief Executive Officer

Hans-Beat Guertler

67 2011 Vice Chairman of the Board of Directors

Donato Spota

Member of the Management Board, Chief Financial Officer

Heidi McDaid

2013 Head of Global Human Resources

Ingrid Heinze-Krauss

2006 Member of the Management Committee, Chief Technology Officer

Laurenz Kellenberger

2009 Member of the Management Committee, Chief Scientific Officer

Achim Kaufhold

2010 Member of the Management Committee, Chief Medical Officer

Daniel Lew

65 2003 Member of the Board of Directors

Thomas Rinderknecht

48 2011 Member of the Board of Directors

Domenico Scala

48 2011 Member of the Board of Directors

Claude Schreiner

71 2007 Member of the Board of Directors

Steven Skolsky

57 2011 Member of the Board of Directors

Thomas Werner

48 2011 Member of the Board of Directors

Barbara Zink

Head - Corporate Development

Biographies

Name Description

Werner Henrich

Mr. Werner Henrich has been Chairman of the Board of Directors at Basilea Pharmaceutica AG since October 2001. From February 2001 to October 2001, he has served as Chief Executive Officer at the Company, and was Member of the Board of Directors of the Company from 2000. He has education as Chemist and European Patent Attorney. He worked for F. Hoffman-La Roche Ltd. (Roche) for over 30 years. Mr. Henrich held various positions at Roche including Head of Global Intellectual Property and Pharmaceutical Licensing for over 12 years. He was also Member of Roche Pharmaceutical Division Executive Board, where he was responsible for intellectual property activities of all Roche divisions and for pharmaceuticals transactions, as well as product acquisitions. Mr. Henrich retired from Roche in November 2003. He is also Member of the Board of Directors of Actelion Ltd. He also acts as Consultant for several biopharmaceutical companies on a part-time basis. He also acted as Consultant to the Company in 2009. Mr. Henrich is Chairman of the Compensation Committee at the Company.

Ronald Scott

Mr. Ronald Scott has been Chief Executive Officer of Basilea Pharmaceutica AG since January 1, 2013. Propr tot hat, he served as Member of the Management Board, Interim Chief Financial Officer, Chief Operating Officer, Executive Director of the Company from October 3, 2011 and before that – as Member of the Management Committee, Chief Financial Officer, Executive Director of the Company from 2004. Prior to joining the Company, he worked for nine years at Roche in management positions in Pharmaceutical Finance, Licensing and the Roche Corporate Finance Mergers and Acquisitions group. His assignments included managing Roche's call, primary and secondary offerings on Genetech, Roche's biotechnology investment portfolio, acquisitions and divestitures. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation as Director in Finance and International Business Development Units, managing divestitures and joint venture transactions.

Hans-Beat Guertler

Mr. Hans-Beat Guertler has been Vice Chairman of the Board of Directors at Basilea Pharmaceutica AG since April 6, 2011. Prior to that he served as Member of the Board of Directors of the Company from April 29, 2009. He holds a Commercial Diploma. He also serves as Management Partner for entrepreneurial investments of Varuma AG and is Member and President of the Boards of Directors of several Swiss-based companies, most of them start-ups and Small and Medium companies (SMEs), primarily in the pharmacy and biotechnology sector. Prior to joining Varuma AG, Mr. Guertler held position of Global Chief Executive Officer of Novartis Animal Health, where he was responsible for the worldwide business, including research, development, manufacturing and marketing of animal pharmaceuticals for pets and farm animals. Previously, he held various management positions at Ciba-Geigy Ltd, including business responsibilities in Eastern Europe, the Northern Hemisphere and the global pest-control business. He was also Chief Executive Officer of Ciba-Geigy Ltd's Seed business company, Mahissa. He has been Member of the Compensation Committee and Audit Committee at the Company since April 29, 2009.

Donato Spota

Mr. Donato Spota serves as Member of the Management Board, Chief Financial Officer of Basilea Pharmaceutica AG. He has over 16 years of experience in the pharma industry, including finance, strategic financial planning and analysis, budgeting, information technology as well as audit and risk management. Prior to his appointment to CFO, he was Basilea’s Global Head of Finance and Services, assuming responsibilities for Finance, Information Technology and General Services. Before joining Basilea in 2002, Mr. Spota worked for F. Hoffmann - La Roche Basel in the area of pharma global informatics financial planning and controlling. He holds a master degree in business administration of the University of Applied Sciences Nuertingen, Germany. He also holds a diploma in information technology.

Heidi McDaid

Ms. Heidi McDaid has served as Head of Global Human Resources of Basilea Pharmaceutica AG since January 1, 2013. She has both business management and human resources qualifications. She has held various positions in finance and administration at Bank und Finanz-Institut AG, Bank CIAL (Schweiz) AG and Lubapharm AG. Before joining Basilea in 2002 as Head of Human Resources, she worked for Mepha AG in the domain of Finance and Human Resources. For many years she served as President of the Board of Trustees of the Basilea Pension Fund and is now member of the Board of Trustees of the collective foundation.

Ingrid Heinze-Krauss

Dr. Ingrid Heinze-Krauss has been Member of the Management Committee and Chief Technology Officer at Basilea Pharmaceutica AG since 2006. She holds a Doctorate in Philosophy degree in Organic Chemistry from Universitaet Freiburg and was Fellow at University of Massachusetts. She joined the Company in 2001 and built up the supply chain management group. Prior to joining the Company, she held a series of managerial positions in Pharma Research at Roche, including Area Head Medicinal Chemistry in Antibacterial Research and Research and Development project management.

Laurenz Kellenberger

Dr. Laurenz Kellenberger has been Member of the Management Committee and Chief Scientific Officer of Basilea Pharmaceutica AG since January 27, 2009. He holds a Doctorate in Philosophy degree in Organic Chemistry from Swiss Federal Institute of Technology (ETH Zuerich). He continued his scientific research at University of Cambridge and at Hoffmann-La Roche, where he held different positions in preclinical research and chemical technologies before joining the Company in 2000. He is author of a number of scientific publications. At the Company, he held various roles of increasing responsibility and served as Head of Chemistry and Member of the Research Management Team with responsibilities for key projects from lead finding and optimization through to preclinical development.

Achim Kaufhold

Prof. Achim Kaufhold, M.D., has been Member of the Management Committee and Chief Medical Officer of Basilea Pharmaceutica AG since February 1, 2010. He holds a medical degree from Universitaet zu Koeln. He worked in the fields of pediatrics, basic and applied medical microbiology, laboratory medicine and infectious diseases in Germany and the United States. He is Professor of Medical Microbiology and Infectious Diseases and Member of the Faculty of Medicine of the University of Aachen. Prof. Kaufhold has spent more than 17 years in senior management positions in the biotechnology and pharmaceutical industry, mainly in leadership roles in research, product and business development, and general management. Prior to joining the Company, he was President & Chief Executive Officer of Affitech A/S, previously Pharmexa A/S. His previous senior management roles included Chief Medical Officer & Vice President of Development, Member of the Executive Committee at Chiron, now part of the Novartis group. He was also Chief Medical Officer, Head of Research, Product & Business Development, Member of the Executive Committee at Berna Biotech, now a Crucell company. He was also Director Clinical Development & Head of the Pediatric Vaccines Development Unit at GlaxoSmithKline Biologicals with global responsibility for the development of that company's pediatric vaccine portfolio.

Daniel Lew

Prof. Daniel Lew has been Member of the Board of Directors at Basilea Pharmaceutica AG since 2003. He is Professor of Medicine at University of Geneva Medical School and Chief of the Service of Infectious Diseases, Department of Internal Medicine at the Geneva University Hospitals. He obtained his Doctorate of Medicine degree from Universite de Geneve in 1976. He specialized in infectious diseases both in Geneva and then subsequently at Harvard Medical School and Massachusetts General Hospital. He is recipient of a number of scientific awards and grants for his research work. He lectures and acts both as Reviewer and Editor for several scientific journals, and is Author of a number of publications on neutrohil function, bacterial pathogenesis and drug resistance. Prof. Lew is President of the International Society for Infectious Diseases (ISID). He is Member of the Audit Committee at the Company and was Member of the Compensation Committee.

Thomas Rinderknecht

Dr. Thomas M. Rinderknecht has been appointed as Member of the Board of Directors at Basilea Pharmaceutica AG as of April 6, 2011. He is an attorney-at-law and senior partner at Badertscher Rechtsanwaelte AG, Zurich and Zug. He has served on the Boards of Directors of several biotech, pharma and medtech companies including Speedel AG, Basel, Glycart Biotechnology AG, Schlieren, and Ganymed Pharmaceuticals AG, Mainz, Germany. He serves as Chairman of Canyon Pharmaceuticals AG, Zug, and Vice-Chairman of APR Applied Pharma Research SA, Balerna. Dr. Rinderknecht holds a PhD in law from the University of Zurich and is admitted to the Bar in Zurich, Switzerland.

Domenico Scala

Mr. Domenico Scala has been appointed Member of the Board of Directors at Basilea Pharmaceutica AG as of April 6, 2011. Prior to joining the Company, he was Chief Executive Officer of Nobel Biocare Holding AG, Switzerland and Chief Financial Officer of Syngenta International AG after holding various managerial positions in Finance with Roche Holding AG. Before joining Roche, he served as Finance Director with Panalpina Italy SpA and Senior Auditor with Nestlé SA. Mr. Scala graduated from the University of Basel with a degree in economics. He holds Executive Development degrees from INSEAD and London Business School.

Claude Schreiner

Mr. Claude Schreiner has been Member of the Board of Directors at Basilea Pharmaceutica AG since March 7, 2007. He studied Economics at the University of Strasbourg (France) and has experience in business and commerce. He started his career at Roche in 1966, and held various positions in the Pharma Division as well as in the Vitamins & Fine Chemicals Division at the Head Quarters in Basel. In 1978, he was appointed Head of the Vitamins & Fine Chemicals Division of Roche in France and subsequently General Manager of Roche’s main agrochemicals company, La Quinoleine SA. In 1990, Mr. Schreiner became Head of the Roche Vitamins & Fine Chemicals Division for Western Europe and later General Manager of Roche France. In 2001 he took over as Head of Western European Pharma Operations and became a Member of the Roche Pharma Division Executive Committee. Mr. Schreiner has retired from Roche at the end of May 2007 but he still holds various board memberships in affiliated companies of Roche Holding Ltd, Basel, in Europe. He became Chairman of the Audit Committee of the Company in 2009. He is also Member of the Compensation Committee at the Company. He also acted as Consultant to the Company.

Steven Skolsky

Mr. Steven D. Skolsky has been appointed Member of the Board of Directors at Basilea Pharmaceutica AG as of April 6, 2011. Prior to that he served as Vice Chairman of the Board of Directors of the Company since April 29, 2009. He has served as Member of the Board of Directors from March 19, 2008 until April 29, 2009. He holds a Bachelor of Arts degree in Biology from University of North Carolina at Chapel Hill. He has many years experience in general management in pharmaceutical industry with emphasis on product strategy, commercialization and product development. He also serves as President and Chief Executive Officer of Sequoia Pharmaceuticals. Prior to appointment at Sequoia Pharmaceuticals, he held position of Chief Executive Officer at Trimeris Inc. Previously, he served at GlaxoSmithKline in a range of senior leadership roles, including Senior Vice President, Global Product Strategy and Clinical Development, and Managing Director of that company's operations in Australia and New Zealand. He is Member of the Compensation Committee at the Company.

Thomas Werner

Dr. Thomas Werner has been Member of the Board of Directors at Basilea Pharmacetica AG as of November 29, 2011. He has over 28 years of experience in the pharmaceutical industry, most recently as Senior Vice President of GlaxoSmithKline where he was Managing Director for Germany and also coordinated the European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. Dr. Werner sits on the boards of SkyePharma plc, Medigene AG, 4SC AG and SuppreMol GmbH as well as on the board of trustees of the Paul Ehrlich Foundation. He holds a degree in chemistry from the University of Goettingen.

Barbara Zink

Basic Compensation

Search Stocks